Good Life Advisors LLC Has $577,000 Stake in Gilead Sciences, Inc. $GILD

Good Life Advisors LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,205 shares of the biopharmaceutical company’s stock after acquiring an additional 476 shares during the period. Good Life Advisors LLC’s holdings in Gilead Sciences were worth $577,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $215,000. Edgestream Partners L.P. increased its stake in Gilead Sciences by 99.0% in the first quarter. Edgestream Partners L.P. now owns 18,401 shares of the biopharmaceutical company’s stock valued at $2,062,000 after acquiring an additional 9,152 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Gilead Sciences by 24.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 94,286 shares of the biopharmaceutical company’s stock valued at $10,565,000 after purchasing an additional 18,368 shares in the last quarter. Finally, Graypoint LLC lifted its stake in Gilead Sciences by 8.6% during the first quarter. Graypoint LLC now owns 12,156 shares of the biopharmaceutical company’s stock worth $1,362,000 after purchasing an additional 965 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the sale, the insider owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 94,646 shares of company stock valued at $11,311,286 in the last ninety days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 0.1%

Shares of NASDAQ GILD opened at $125.02 on Friday. The firm has a 50 day moving average price of $117.44 and a two-hundred day moving average price of $112.77. The stock has a market cap of $155.11 billion, a P/E ratio of 24.90, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $127.68. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GILD shares. Morgan Stanley boosted their price target on Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Daiwa Capital Markets raised their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Finally, The Goldman Sachs Group raised their price objective on Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.13.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.